Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 728 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR We’re asking scientists to tackle 9 of the toughest challenges in... October 14, 2020 Fruquintinib Prolongs Survival Compared with Placebo in Heavily Pretreated Patients with... June 27, 2023 EMA Recommends Extension of Indications for Sugemalimab October 28, 2025 EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... October 6, 2023 Load more HOT NEWS Gift Giving During a Pandemic In Memory of Håkan Mellstedt: Former ESMO President Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among... Study Finds Possible New Treatment for Metastatic Breast Cancer That Has...
